ERBB2 and breast carcinoma: HER2 overexpression is found in 10–15% of breast cancer patients, for whom targeted HER2 therapies have become standard treatment and have increased the progression-free survival by up to 50% (Harbeck and Gnant 2017; Altena et al. 2023; Seban et al. 2023).